Rheumatology Science and Practice · 2020 · 21 citations · 12 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyImmunopharmacologyRheumatologyAnkylosing SpondylitisAnti-inflammatory PharmacologyCytokine-based TherapyInflammatory ArthritisInflammatory Disease PharmacotherapyPsoriatic ArthritisDisease-modifying Anti-inflammatory DrugsInterleukin 17 InhibitionInterleukin-17 InhibitorsInterleukin-17 PathwayNonsteroidal Anti-inflammatory Drug SafetyPlacebo ComparatorsPsoriasis TherapyPsoriatic Disease
Netakimab (NTK) is a humanized anti-interleukin-17А (IL-17A) monoclonal antibody approved for the treatment of psoriatic arthritis, ankylosing spondylitis, moderate to severe psoriasis. Here, we present the results of the 24-weeks double blind period of the PATERA study. Objective . The objective of the study was to evaluate the efficacy and safety of NTK compared to placebo in patients with psoriatic arthritis (PsA). Patients and methods . 194 patients with active PsA with an inadequate response to previous therapy with nonsteroidal anti-inflammatory drugs, conventional or biologic disease-modifying antirheumatic drugs, were randomized in a 1:1 ratio to receive subcutaneous 120 mg NTK or placebo at weeks 0, 1, 2, 4, 6, 8, 10, 14, 18, 22. At week 16 ACR20 (20% improvement in the American College of Rheumatology response criteria) non-responders in placebo group were reassigned to NTK in a blinded manner. The primary endpoint was the proportion of patients achieved ACR20 response at week 24. Results . 82,5% of patients in the NTK group and 9.3% of patients in the placebo group achieved ACR20 at week 24 with the 95% CI [0,63; 0,84] ( p < 0,0001). Skin manifestations and axial disease significantly improved with NTK. The safety profile of NTK was comparable to placebo. The most frequent treatment-related AEs were expected and common for all other IL-17 inhibitors: increased alanine aminotransferase (ALT), infections, lymphopenia. Conclusion . NTK in the dose of 120 mg has superior efficacy over placebo in patients with active psoriatic arthritis. The safety profile is consistent with other IL-17 inhibitors.
12
Iain B. McInnes, Philip J. Mease, Bruce Kirkham et al. · The Lancet · 2015 · 850 citations
Philip J. Mease, Désirée van der Heijde, Masato Okada et al. · Annals of the Rheumatic Diseases · 2016 · 568 citations · Full text